Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. - Wikidata - wikimedia - TriplyDB

Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.

Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.

http://www.wikidata.org/entity/Q33658913

about

Oligonucleotide therapeutic approaches for Huntington disease Disease-modifying therapeutic directions for Lewy-Body dementias Parkinson's disease: gene therapies The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease Progress toward in vivo use of siRNAs-II Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease Alpha-synuclein repeat variants and survival in Parkinson's disease A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease.shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224.Parkinson's disease and α-synuclein expression Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?The genetics of Parkinson's disease: progress and therapeutic implications Recent advances in RNA interference therapeutics for CNS diseases.Up-regulation of SNCA gene expression: implications to synucleinopathies Gene-based therapies in Parkinson's disease.Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations RNA Interference of Human α-Synuclein in Mouse.α-Synuclein in Parkinson's disease.α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications.Overcoming obstacles in Parkinson's disease.α-Synuclein and mitochondrial dysfunction in Parkinson's disease.Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Advances in the genetics of Parkinson disease.Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?Genetics and genomics of Parkinson's disease.Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease.Down-regulating α-synuclein for treating synucleopathies.Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.

P2860

Q22306293-DE227652-5ADE-42AE-81C3-F651E96D6CF3 Q26782907-F8BEA901-1D88-4F8B-AD7D-B8BB906AE0EC Q26824184-0C134712-4188-4397-BF04-992F7350208B Q28068464-D4A43106-476A-46E8-8695-4E75E50FFE5E Q28255877-6CF9F4C9-C153-4336-8587-EC259B67CDE9 Q28547585-4B815AE9-2BC9-4980-9F69-2A24786B2FF3 Q33617563-CF4CBF80-F8BF-450A-AEDC-3AF593697EF9 Q33636374-F2304BC4-BD2F-40EB-8833-7453ACB0264B Q34231155-683FDA5F-DE2E-409C-B15E-E0CDC5657618 Q34795038-3FF985B9-CC3A-4D72-8E41-2F1E06E0B845 Q35054395-5AD68878-6866-4806-9FCF-3EA1E6974BBE Q35814444-6C455E6F-FCE2-4ECC-9DC9-72CC510A2146 Q36040166-F563A3BC-C4D8-4A1F-8D4B-C7E4A58C4B9F Q36341509-391D3E6F-E976-449D-B339-5A3F556320A8 Q36346542-0FA200AF-C4A8-477C-AE55-C83515B05ECA Q36454426-9D828B9B-FF95-4E79-A487-D5A0914425FE Q36491690-7BA84003-C30C-46D2-BC63-1A76B5F171E6 Q36626825-65E57DE8-1BAB-46C9-BB54-977CDA68A65A Q36983193-3674121C-3A2F-4A18-A0CD-40738E3D022A Q37004246-F48CF0EC-DB55-4754-96E9-2A52D155755E Q37506503-6D78A90F-1B17-4A4E-BD44-CEC73AA4013C Q37566684-E26B92CF-A11C-4AE5-BB53-0078195E927A Q37614503-CCADC4D6-DC02-46E8-B0E5-4BC5AB3E62BA Q37987146-54B02D3A-DEBF-4EFE-B019-84D59F213CDB Q38040282-564A8E7B-E9D3-4714-A217-B52294F73DF8 Q38056875-727A25B0-7CAA-4EF9-A637-CC5DA9980BB9 Q38077665-515685FA-0119-46F7-B309-A72A969DB2BB Q38085689-5735D3DD-21E5-4581-8BF7-5DFA6B4D4300 Q38112216-80C673A1-3627-4142-AAB1-52ABDF3BCDC4 Q38121773-3AD87F58-3CF4-4E53-84BB-F08E528909B9 Q38128456-527CB99D-A704-4643-A0CC-57CFB4E9D875 Q38233866-65347AB5-8024-434F-A6D6-73378B9FF411 Q38607819-11302581-FCCB-467F-839A-2B1AD31FB42F Q38823785-13129ADF-D8D4-4DBD-9DE8-60B16885CC42 Q41874717-7D8845CE-3275-4F80-8521-DFED95367AEE Q42711308-44FEA777-A0BB-40F8-8A6C-0726F1B060E9 Q46354756-FA86ED1D-193A-46C6-9E95-04A472703245 Q47130088-CD24CEDF-FBF5-435A-9EEB-0211277674E3 Q48548334-885CD7A7-519A-42A9-A838-B6C7DEFE0E65 Q50335089-8896AC8D-2C06-41F0-B933-F814DF99D5D7

P2860

Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.

http://www.wikidata.org/entity/Q33658913

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Alpha-synuclein suppression by ...... the primate substantia nigra.

@ast

Alpha-synuclein suppression by ...... the primate substantia nigra.

@en

type

label

Alpha-synuclein suppression by ...... the primate substantia nigra.

@ast

Alpha-synuclein suppression by ...... the primate substantia nigra.

@en

prefLabel

Alpha-synuclein suppression by ...... the primate substantia nigra.

@ast

Alpha-synuclein suppression by ...... the primate substantia nigra.

@en

P1433

Q33658913-4B7F673F-7894-4D3B-B73C-57B42F619E04

P1476

Q33658913-FC6DC8A6-34EF-4723-B212-6C5A8D72BF5D

P2093

Q33658913-1E3C1CBF-FB75-410F-8A95-5D487E6A3AD3

Q33658913-5914DB08-BE38-4973-ACF7-57A76EFCA6BC

Q33658913-89098019-C013-46B0-8E11-B2C9187054A6

Q33658913-FE092B39-6D62-4120-A81B-1F37F2925B44

P2860

Q33658913-042FF250-11BC-45E6-83DE-729FD4C70CB7

Q33658913-074B3F4F-C017-48D3-BF7E-FCDF5F0DE3BD

Q33658913-082D0CD2-8687-4E4A-A2E1-B67FD2B9CFCC

Q33658913-0B5DA3DF-6818-4DDF-89C4-6E134DF444A8

Q33658913-12C32F8C-00B7-4D8E-9786-926C11891EA8

Q33658913-17C87A81-3CF8-4B76-B7E7-D3951603380E

Q33658913-19D4AD2C-E0FC-4888-B807-8405F587D3A8

Q33658913-25F7D90E-D0E1-4C4E-A782-46D4773B049B

Q33658913-36377F79-CAA7-4E15-BB7C-2B6766961BA7

Q33658913-3F02321C-3486-48C5-A8CF-433BABB0F1CB

P304

Q33658913-06029D00-5543-47C0-8D9C-6EEF6F0C173F

P31

Q33658913-F2678342-4427-4841-9521-62F78CBD97E1

P356

Q33658913-B8B8ED2C-0E59-4DAF-8031-CE47DEFC7E32

P407

Q33658913-1B8304D7-C6CA-4B44-876B-1B45F59A0AE7

P433

Q33658913-23826019-F07D-4D3C-9A07-65F167FF5D69

P478

Q33658913-A4D5EEEF-DA7D-430B-8CFE-BE7EDFFADF54

P50

Q33658913-ADF01A7D-A7BC-4C04-A552-D69219A88EA6

Q33658913-C9141D81-FA5D-4E0E-AC39-98DEBE0527A3

P577

Q33658913-5407104F-1ABC-4CCE-A5CE-BAB966F28394

P5875

Q33658913-C07074D8-845C-4157-888D-8F46356589B8

P698

Q33658913-60F18A9A-0DA7-4DA3-8173-52164F38DE1C

P921

Q33658913-4AEB41B1-BE7F-4437-827D-37512B05915D

Q33658913-F5A7032B-92B6-4E06-B64D-F547C3F4C354

P932

Q33658913-D95B49AC-A051-4545-ADAE-1208D0EB0F9B

P356

JOURNAL.PONE.0012122

P1433

P1476

Alpha-synuclein suppression by ...... the primate substantia nigra.

@en

P2093

Alison L McCormack

http://www.w3.org/2001/XMLSchema#string

David Bumcrot

http://www.w3.org/2001/XMLSchema#string

Donato A Di Monte

http://www.w3.org/2001/XMLSchema#string

Sally K Mak

http://www.w3.org/2001/XMLSchema#string

P2860

alpha-Synuclein and neuronal cell death

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

alpha-Synuclein locus triplication causes Parkinson's disease

Staging of brain pathology related to sporadic Parkinson's disease

Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

P304

e12122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0012122

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Matthew J. Farrer

Jaimie M Henderson

P577

2010-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45651368

http://www.w3.org/2001/XMLSchema#string

P698

20711464

http://www.w3.org/2001/XMLSchema#string

P921

substantia nigra

P932

2920329

http://www.w3.org/2001/XMLSchema#string